Dr. Phil Skolnick
fentanyl it's to of To you, unique of data properties crisis. the OPNTXXX, exacerbated helpful health pharmacological the like understand this understand opioids worsening Thank public Roger. how they've significance synthetic for and our
Next slide, please. Thank you.
onset opioids rapid receptors. property window into effectively of system as and lipophilic central First, onset analgesic opioids, and as actions. nervous receptors overdose. well effects depressant person's the an shortens mediate rescue in of fentanyl the molecules a These This for rewarding opportunity rapid opioid a a entry other successful binds a rapid to to synthetic respiratory Like more much the action. of heroin. This like very fentanyl, like results in highly opioids our compared opioids
high in a is activating potent the stronger and compound with overdose heroin. the very greatly affinities binding associated synthetic risk than mu-opioid high related and brain, into rapid increase signaling potency fentanyl very a addition for XXx receptor milligram per milligram On However, Both about a opioids, are in entry pathways. like synthetic to with basis, opioids. fentanyl
termed complexity other indicating is fentanyl treating of emerged Health the overdose with eight means Lastly, opioid effective about an level yet fentanyl rescue amount overdose, context which reversal of naloxone is can more include risk the is taken effects opioid opioid respiratory with reports needed opioid symptoms an depression infusion the wears are "stronger, the agent. management and in half-life lead need a has or synthetic of information have well naloxone, any to is plasma formulations that the the reversal overdose, error symptoms plasma renarcotization. over than the overdose, reversal adding duration because after agent This only overdoses. of half-lives the an antagonist to receptor can the Like half-lives off. when a longer in intravenous opioids Institutes this either can has of of if a of another the called no room. complicates where to can seen National illicit we've action including is there that emergency reversal antagonists". hours. years, to of development a as FDA-approved of that the need as majority nalmefene Naloxone agents Renarcotization of can reduce naloxone the agent opioid widely past hours currently signs extended a with the within seven two recurrence longer-acting five overdose, renarcotization. and reoccur a Multiple for to for half-life agent the leadership plasma many are The opioids of high-potency a of is depression. This It redose about as responsible one of synthetics in vary of the to is phenomenon rescue for longer reverse agent, respiratory mu-opioid
pharmacokinetic such a suited I so. clinical as learned particularly that may environment to as well large nalmefene reversal a as is as demonstrate information fentanyl. community research now it why development a our we program use dominated of properties differentiate However, pharmacodynamic believe existing and synthetics by body agent, this of well to from the own
you. higher new much Multiple five-fold have compared higher studies at that occupancy receptor demonstrated results has receptor new affinity Thank a the nalmefene naloxone, please. in opioid plasma higher opioid affinity even concentrations. slide, to similar Next than naloxone. This if
demonstrated points, critical the five have that higher at naloxone. successful minutes. concentration study for nalmefene show rescue. a pharmacokinetic plasma is to study PKXXX Illustrated reported for Our Xx Data at our This time compared plasma nasal are here from nasal of especially nalmefene our that is naloxone. nasal concentration concentrations early almost plasma important of
by Cmax, here total naloxone. in and illustrated minutes It to that Tmax nasal to of contrast XX nalmefene also You the Cmax. the here of this can in see minutes nasal with Tmax the twice nasal XX and plasma agent is naloxone, reversal the reach concentration took
including hours two longer to Finally, XX is at hours. X our naloxone substantially the studies, plasma nalmefene own demonstrated at to half-life have of multiple one that than
In as the changes healthy nasal ventilation, of naloxone point naloxone naloxone -- compared non-inferiority of in effect pharmacodynamic to in to good designed The opioid study. respiratory the the was completed a Minute of reversing to in nasal The depressed depression. at by per minute. conducted minute to FDA. respiratory addition good nasal inhaled nalmefene nasal FDA, This is study following agreed exhaled depression. This least This volunteers remifentanil. minutes nalmefene opioid-induced or was recently crossover respiratory to to this naloxone assessed amount ventilation at request in nasal drugs show these of drug. with experimental as the powered nasal PK nalmefene model be primary study measuring an to respective data the of as compare nasal as endpoint at also demonstrating the administration to five This synthetic air were two as good post-administration. the at means time in opioid-induced as reversing be the we
nalmefene the randomized where of day primary early because the rescue indicated on one critical an drugs. or window quickly in fact, to for of successful receive to it minutes post-administration. in five five This in a case study a as point either either is before, is, endpoint was Our or reduced to to washout measure between overdose, there I with act time opportunity agreed be agent day was were especially An endpoint, able in synthetic the naloxone important as is primary rescue. Subjects to a overdose. affect
five the Next the first extreme this what all at you. the slide, of subjects I'll primary time also mask minutes as we then explain of will Thank which procedure, the see containing and study. mixture high can in the how illustrates figure endpoint, start, XX on I graph, face left gas study. we To a conducted out fitting a please. tight the minutes subjects go see This through administered zero, you were concentration COX. were to
this can and minute graph says and it started, You point, hypercapnic that the by the Remi you remifentanil in of infusion study. This At end which lasted see by after XX the was see was increased. inflation downward substantially can of I&F. mixture, that started arrow, at breeding minutes point infusion this the gas through infusion this that
on of ventilation. which see graph, subjects remifentanil depression. the reduction and indicated can experimental minutes is removed XX rapid course, first or a XX the ventilation intranasally measured Minute At of infusion, produced face is either five model naloxone. over the minutes, remifentanil briefly that respiratory the includes which minutes, was then in central is reduction dosed the primary on the that at minutes to which, endpoint the by time XX nalmefene were It You was with arrow graph. ventilation is mask downward minutes in into this the that opioid-induced
the Let's in demonstrates bar liters X.XXX you. the And X.XXX ventilation next was slide May of respectively. XX graph left minutes in reversal that nearly the produced that detail. please? nalmefene in Thank examine naloxone, to produced more the Working minute ventilation in from liters minute have these I by the first right, minutes. slide, increases five greater twice naloxone. a minutes respiratory and of depression per nalmefene minute with The per minute and were nasal five
the -- clearly difference between As two the groups see, minute you ventilation the minute in favorsnalmefene. can
between the the criteria naloxone is filled have graphed a difference bracketing by in moving Now is with ventilation established the demonstrate the the line's been the to FDA non-inferiority illustrate circle This figure panel. that interval filled to confidence The circle. is nalmefene to indicated XX% left. middle and minute
the difference minute first net line The That was right out line mean two where no difference. no is there treatments. the is intersect zero, of between would to the the ventilation which
point could that where met The than lower as proposed no the non-inferiority the of left Nalmefene to naloxone. than non-inferiority. of endpoint nalmefene primary second well to OPNTXXX XX% the be falls the more clearly indicating line is we slide, right the
minutes with the shows experimental at And XX model come is of circles pre-remifentanil values, minutes nalmefene, The model of are the effect with first third within X.X, well to minutes close By can and that naloxone respiratory nalmefene remifentanil. within clear also minutes an were the that were nasal depression. and at dot contrast, the at which before -- the reversed. as points post XX% actually be opposed post minute and increase graph, and should the underestimate XX XX This minutes dotted the opioid-induced panel the dosing. five both respect XX, squares. see look slides of nalmefene because between overdose ceiling five onset ventilation Recall took the XX increases confidence you efficacy very values a inflation post minute also differences minute to ventilation true or be At it has The subjects those line an naloxone it. to may or that from levels at you if interval this closely that in cross to can to nalmefene. seen speed given
represents colleague, absorption submission highly please. promising also It the the like FDA. Biomedical studies clinical our the long the that Institute contributions I'd we PK half-life overdose data, a Ellison if attention. these to and form I'd you thank partners, the Next acknowledge Authority clinical conducted, of both demonstrating together suggests on like and plasma studies. NDA OPNTXXX the with These basis their reversal rapid slide, these opioid Research may, support. success for agent. with studies this PD to compelling Mark National at for our of will is your And Advanced of and development Dr. Abuse to my government Drug and Development to Thank his point, team the I
now Let to this David? over me David. hand
